# US 2020/0090783 A1 · Evaluating genetic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0090783 A1
- Document ID: US20200090783A1
- Status: Published application
- Kind: A1
- Application number: 16/692,276
- Filed: 2019-11-22
- Published: 2020-03-19
- Earliest claimed: 2006-05-03
- Assignees: Population Bio, Inc.
- Applicants: Population Bio, Inc.
- Inventors: James CHINITZ; Eli HATCHWELL
- Web page: https://patentgrep.com/patent/US20200090783A1

## CPC

- G16B 20/10: Ploidy or copy number detection
- C12Q 1/6813: Hybridisation assays
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to genetic analysis and evaluation utilizing copy-number variants or polymorphisms. The methods utilize array comparative genomic hybridization and PCR assays to identify the significance of copy number variations in a subject or subject group.

## Claims

### Claim 1

A method of evaluating copy number variants of a subject comprising:
a. obtaining information comprising genomic copy number from said subject,
b. accessing a set of data representing a frequency of occurrence for one or more copy number variants from at least 100 individuals,
c. comparing said information from said subject against said set of data, and
d. evaluating copy number variants of said subject based on the comparison of step (c).

### Claim 2 (depends on 1)

The method of claim 1 wherein said accessing of step (b) and comparing of step (c) are computer-implemented.

### Claim 3 (depends on 1)

The method of claim 1 wherein said information from said subject is obtained by an aCGH analysis.

### Claim 4 (depends on 1)

The method of claim 1 wherein said information from said subject is obtained using PCR analysis.

### Claim 5 (depends on 1)

The method of claim 1 further comprising identifying a probability of said subject possessing a condition associated with a copy number variant.

### Claim 6 (depends on 1)

The method of claim 1 wherein said set of data comprises the frequency information for normal copy number variants.

### Claim 7 (depends on 1)

The method of claim 1 wherein said set of data comprises a copy number breakpoint map.

### Claim 8 (depends on 1)

The method of claim 1, wherein said set of data is genome-wide.

### Claim 9

A computer readable medium, comprising a set of instructions to cause a computer to perform the steps of comparing input data comprising copy number information from a subject's genome against a set of data comprising frequency data for copy number variants from the genome of at least 100 individuals and generating an output comprising an evaluation of the copy number variant of said subject.

### Claim 10 (depends on 9)

The computer readable medium of claim 9 wherein said set of data comprises data from at least 1,000 individuals.

### Claim 11 (depends on 9)

The computer readable medium of claim 9 wherein said data comprises data from at least 5,000 individuals.

### Claim 12 (depends on 9)

The computer readable medium of claim 9 wherein said data comprises data from at least 10,000 individuals.

### Claim 13 (depends on 9)

The computer readable medium of claim 9 wherein said set of data comprises the frequency information for normal copy number variants.

### Claim 14 (depends on 9)

The computer readable medium of claim 9 wherein said set of data comprises a copy number breakpoint map.

### Claim 15 (depends on 9)

The computer readable medium of claim 9, wherein said set of data is genome-wide.

### Claim 16

A method of identifying whether a therapeutic is useful for treating a condition comprising: obtaining information from the genome of a cohort of subjects involved in a clinical trial of a therapeutic for said condition, identifying the existence of one or more copy number variants, comparing said one or more variants from said cohort to data representing the frequencies of copy number variants in at least 100 individuals to determine the relevance of said one or more variants, correlating a success rate of said therapeutic to the existence and relevance of said copy number variants in said cohort, thereby identifying said therapeutic as useful.

### Claim 17 (depends on 16)

The method of claim 16 further comprising identifying one or more subpopulations from said cohort in whom the success rate permits the rescue of a therapeutic from said clinical trial.

### Claim 18 (depends on 16)

The method of claim 16 wherein said data is from at least 1,000 individuals.

### Claim 19 (depends on 16)

The method of claim 16 wherein said data is from at least 5,000 individuals.

### Claim 20 (depends on 16)

The method of claim 16 wherein said data is from at least 10,000 individuals.

### Claim 21 (depends on 16)

The method of claim 16 wherein said data comprises the frequency data for normal copy number.

### Claim 22 (depends on 16)

The method of claim 16 wherein said data comprises a copy number breakpoint map.

### Claim 23 (depends on 21)

The method of claim 21 wherein said data is genome-wide.

### Claim 24 (depends on 16)

The method of claim 16 further comprising screening the genome of said cohort to obtain said information.

### Claim 25 (depends on 16)

The method of claim 16 wherein said information comprises data from aCGH.

### Claim 26 (depends on 16)

The method of claim 16 wherein said information comprises date from PCR.

### Claim 27

A method of reviewing the efficacy of a therapeutic approved for treating a condition comprising: obtaining information from the genome of a cohort of subjects using said therapeutic for said condition, which information identifies the existence of one or more copy number variants, comparing said one or more variants from said cohort to data representing the frequencies of copy number variants in at least 100 individuals to determine the relevance of said one or more variants, and correlating a beneficial and/or adverse effects of said therapeutic to the existence and relevance of said copy number variants in said cohort.

### Claim 28 (depends on 27)

The method of claim 27 further comprising screening the genome of said cohort to obtain said information.

### Claim 29 (depends on 27)

The method of claim 27 further comprising identifying one or more subpopulations from said cohort, which subpopulations are associated with an extent of success or deleterious affects.

### Claim 30 (depends on 27)

The method of claim 27 wherein said data is from at least 1,000 individuals.

### Claim 31 (depends on 27)

The method of claim 27 wherein said data is from at least 5,000 individuals.

### Claim 32 (depends on 27)

The method of claim 27 wherein said data is from at least 10,000 individuals.

### Claim 33 (depends on 27)

The method of claim 27 wherein said information comprises data from aCGH screening.

### Claim 34 (depends on 27)

The method of claim 27 wherein said information comprises data from PCR screening.

### Claim 35

A method of reviewing the efficacy of a therapeutic approved for treating a condition comprising: obtaining information from the genome of a cohort of subjects using said therapeutic for said condition, which information identifies the existence of one or more copy number variants, comparing said one or more variants from said cohort to data representing the frequencies of copy number variants in at least 100 individuals to determine the relevance of said one or more variants, and correlating a beneficial and/or adverse effects of said therapeutic to the existence and relevance of said copy number variants in said cohort.

### Claim 36 (depends on 35)

The method of claim 35 further comprising screening the genome of said cohort to obtain said information.

### Claim 37 (depends on 35)

The method of claim 35 further comprising identifying one or more subpopulations from said cohort, which subpopulations are associated with an extent of success or deleterious affects.

### Claim 38 (depends on 35)

The method of claim 35 wherein said data is from at least 1,000 individuals.

### Claim 39 (depends on 35)

The method of claim 35 wherein said data is from at least 5,000 individuals.

### Claim 40 (depends on 35)

The method of claim 35 wherein said data is from at least 10,000 individuals.

### Claim 41 (depends on 35)

The method of claim 35 wherein said information comprises data from aCGH screening.

### Claim 42 (depends on 35)

The method of claim 35 wherein said information comprises data from PCR screening.
